Cancer Prevention, Control, and Survivorship Research Program

Mayo Clinic Rochester, Rochester MN

Investigators

Linked publications, trials & patents

Abstract

CANCER PREVENTION, CONTROL, AND SURVIVORSHIP (CPCS): ABSTRACT Cancer Prevention, Control, and Survivorship (CPCS) is one of two newly reorganized Mayo Clinic Comprehensive Cancer Center (MCCCC) Research Programs focused on Cancer Population Sciences, formed in 2023 along with the Cancer Risk Assessment, Early Detection, and Interception (REDI) Research Program. CPCS drives innovative research across the cancer control continuum to reduce cancer risk and burden, overcome poorer cancer outcomes across all populations, and enhance quality of life and function during and after cancer treatment. CPCS catalyzes the translation of scientific discovery into improved patient and population outcomes through three specific aims: 1) cancer risk assessment and prevention; 2) diagnosis and treatment decision-making; and 3) symptom control and survivorship. The program has three crosscutting, community-responsive strategic priorities: 1) evidence-based interventions; 2) cancer communications; and 3) use of artificial intelligence (AI) to drive programmatic science. The aims and strategic priorities reflect the combined expertise of 53 members (34 MCR, 10 MCA, 9 MCF) from 21 departments, including 22 newly recruited faculty, with expertise in epidemiology, cancer incidence and outcome differences in populations, community-engaged research, and behavioral, communication, and implementation science. CPCS is led by Janice Krieger (MCF), Kathryn Ruddy (MCR), and Lila Rutten (MCR), with Emerging Leaders Diane Ehlers (MCA) and Pooja Advani (MCF) who facilitate interactions with the Community Outreach and Engagement (COE) and the Cancer Research Training and Education Coordination (CRTEC) Offices. Key achievements include conducting pragmatic trials that increased HPV vaccination and reduced cancer symptoms (MCR); enhancing research and clinical trial participation and promoting decentralized trials (MCF); and advancing the understanding of physical activity and brain health in survivorship through community partnerships (MCA). CPCS members hold $8.1M in cancer relevant peer-reviewed annual funding ($6M from NCI). Of 1592 program publications in 2019-2023, 19% were intra-programmatic, 37% inter-programmatic, 54% were collaborative with other NCI Centers, and 20% had impact factors >10. CPCS-affiliated interventional trials accrued 172,230 participants between 2019-2023; non-interventional trial accruals were 163,281. These robust accruals have enabled policy-changing, practice-changing, and paradigm shifting work within and across MCCCC catchment areas. CPCS future directions have been developed in alignment with the MCCCC 2030 Bold. Forward Strategic Plan through intra- and inter-programmatic retreats and discussions. Planned recruitment, pilot funding, and training align with MCCCC strategic goals of transforming cancer care delivery, artificial intelligence and data science, development of decentralized clinical trials and integration of novel technologies to facilitate research, enhance patient experience, and improve population health.